Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

HLS Therapeutics Inc. (T:HLS)

Business Focus: Pharmaceuticals Wholesale

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for HLS within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jul 02, 2024 07:00 ET
HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust
Total consideration of up to $45.75 million, which consists of upfront cash, sales-based milestone payments and DRI Healthcare's assumption of future milestone payment obligationsHLS will use the upfront cash proceeds to pay down debt2024 revenue and Adjusted EBITDA guidance is updated to reflect effective sale date of June 28, 2024TORONTO, July 2, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has sold its royalty intere
Read full article
Jun 07, 2024 19:00 ET
HLS Therapeutics Reports Annual Meeting Results
TORONTO, June 7, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 7, 2024.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.08
--
--
Price to Sales - TTM
1.32
0.67
3.34
Price to Book - most recent quarter
0.91
0.91
2.17
Price to Cash Flow per share - TTM
47.50
--
11.23
Price to Free Cash Flow per share - TTM
7.22
7.22
18.13
See all valuations

Short Report

Date Number of Shares Shorted Net Change
Jun 30, 2024 38,838 -3,015
Jun 15, 2024 41,853 3,407
May 31, 2024 38,446 -29,840
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.

See business summary

 

Twitter

Search (past week) for $HLS.CA

  • No tweets found